<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2732">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701532</url>
  </required_header>
  <id_info>
    <org_study_id>P070150</org_study_id>
    <nct_id>NCT00701532</nct_id>
  </id_info>
  <brief_title>Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction</brief_title>
  <acronym>CAIMAN</acronym>
  <official_title>Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -Context: Study objectives Primary: impact of modafinil versus placebo on DAT density&#xD;
      modifications in the striatal and extra-striatal regions in cocaine dependent subjects&#xD;
      hospitalised from D3 to D21.&#xD;
&#xD;
      Primary Hypothesis:&#xD;
&#xD;
      More rapid normalisation of DAT concentrations measured by PET using modafinil versus placebo&#xD;
      from D3 to D21 during cocaine detoxification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context:&#xD;
&#xD;
      Cocaine dependence is a disorder with a rapidly progressive evolution, associated with&#xD;
      various complications. Because of cocaine's direct action on the dopamine transporter (DAT),&#xD;
      dopaminergic system dysregulation plays a fundamental role in reinforcement phenomenon and in&#xD;
      dependence. This has been proven in numerous animal and post-death human studies of striatal&#xD;
      DAT. In vivo studies in cocaine dependent patients are rare. Currently no pharmacotherapy is&#xD;
      available to treat this pathology. Current studies indicate that pharmacological agents such&#xD;
      as modafinil may be able to reverse the neuroadaptations induced by cocaine dependence.&#xD;
      However, no functional neuroimaging study (Positron Emission Tomography, PET) has analysed&#xD;
      the impact of medications on DAT density in cocaine dependent patients. However, in primates,&#xD;
      in vivo PET has shown modafinil affinity for DAT.&#xD;
&#xD;
      Primary Hypothesis:&#xD;
&#xD;
      More rapid normalisation of DAT concentrations measured by PET using modafinil versus placebo&#xD;
      from D3 to D21 during therapeutic cocaine withdrawal.&#xD;
&#xD;
      Study objectives Primary: impact of modafinil versus placebo on DAT density modifications in&#xD;
      the striatal and extra-striatal regions in cocaine dependent subjects hospitalised from D3 to&#xD;
      D21.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.&#xD;
      Correlation between craving measurements, depressive symptom measurements and cognitive&#xD;
      deficit measurements observed and modifications of DAT density.&#xD;
&#xD;
      Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.&#xD;
&#xD;
      Tolerance and safety evaluation of high modafinil doses, measured by adverse events and&#xD;
      biological parameters.&#xD;
&#xD;
      Calculation of the number of subjects: A power of 90% is found for a number of subjects&#xD;
      estimated at 24 (bilateral test, α risk at 5%, estimated SEM of 5%, variation of the&#xD;
      occupational concentration of the DAT expected to be at least 12% in the modafinil group).&#xD;
      Considering the usual rate of patients lost to follow-up in this patient population (25%), we&#xD;
      plan to include 30 patients.&#xD;
&#xD;
      Methodology: This study is regulated by the law on biomedical research of August 9, 2004. It&#xD;
      is a randomised monocentric double blind study versus placebo. During the study, for 90 days,&#xD;
      patients will receive in double blind either modafinil or placebo according to their&#xD;
      randomisation arm.&#xD;
&#xD;
      Evaluations will include 2 PET, cerebral MRI, blood work-up, urinary toxin screen, clinical&#xD;
      scales for craving, depression and neuropsychological evaluations.&#xD;
&#xD;
      Patients will be recruited over 24 months. The total study length will be 36 months.&#xD;
&#xD;
      Primary judgment criteria: Variation of the linking potentials (specific fixation rate for&#xD;
      the radioligand [11C]-PE2I to DAT) between the TEP measurement on D3 and D21 within the&#xD;
      various anatomical region of interest between the 2 groups (modafinil, placebo).&#xD;
&#xD;
      Expected Results: Decreased DAT occupation rates in the modafinil group versus placebo from&#xD;
      D3 to D21 of withdrawal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification.</measure>
    <time_frame>day 3 and day of cocaine detoxification</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.</measure>
    <time_frame>D3 to D90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density.</measure>
    <time_frame>D3 to D21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.</measure>
    <time_frame>D3 to D21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters.</measure>
    <time_frame>D3 to D90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Cocaine Addiction</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil and PET (brain imaging)</intervention_name>
    <description>duration 90 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>duration 90 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men of at least 18 years of age&#xD;
&#xD;
          -  Cocaine dependent according to DSM IV TR criteria&#xD;
&#xD;
          -  Seeking treatment&#xD;
&#xD;
          -  Capable of understanding and giving their informed written consent&#xD;
&#xD;
          -  With National Health coverage&#xD;
&#xD;
          -  Urinary screen positive for cocaine in the weeks prior to inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women&#xD;
&#xD;
          -  Other DSM IV TR axe I diagnostic criteria (except for tobacco)&#xD;
&#xD;
          -  Neurological disorders&#xD;
&#xD;
          -  Treatment that interferes with the DAT and modafinil&#xD;
&#xD;
          -  Contraindications for modafinil and Magnetic Resonance Imaging&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Reynaud, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris Hôpital Paul Brousse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unité de recherche U797 Inserm - CEA - Université Paris-Sud. &quot; Neuroimagerie &amp; Psychiatrie &quot; Service Hospitalier Frédéric Joliot</name>
      <address>
        <city>Orsay</city>
        <zip>91401</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine</keyword>
  <keyword>Substance abuse</keyword>
  <keyword>Addiction</keyword>
  <keyword>Dependence</keyword>
  <keyword>Modafinil</keyword>
  <keyword>Brain imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

